CR20200088A - Compuestos espirocíclicos y sus métodos de preparación y uso - Google Patents

Compuestos espirocíclicos y sus métodos de preparación y uso

Info

Publication number
CR20200088A
CR20200088A CR20200088A CR20200088A CR20200088A CR 20200088 A CR20200088 A CR 20200088A CR 20200088 A CR20200088 A CR 20200088A CR 20200088 A CR20200088 A CR 20200088A CR 20200088 A CR20200088 A CR 20200088A
Authority
CR
Costa Rica
Prior art keywords
making
methods
same
compounds
spirocycle
Prior art date
Application number
CR20200088A
Other languages
English (en)
Inventor
Olivia D Weber
Daniel J Buzard
Michael B Shaghafi
Cheryl A Grice
Original Assignee
Lundbeck La Jolla Research Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck La Jolla Research Center Inc filed Critical Lundbeck La Jolla Research Center Inc
Publication of CR20200088A publication Critical patent/CR20200088A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente se proporcionan compuestos y composiciones útiles como moduladores de MAGL. Además, los compuestos y las composiciones en cuestión son útiles para el tratamiento del dolor.
CR20200088A 2017-08-29 2018-08-28 Compuestos espirocíclicos y sus métodos de preparación y uso CR20200088A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762551714P 2017-08-29 2017-08-29
PCT/US2018/048388 WO2019046330A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
CR20200088A true CR20200088A (es) 2020-04-08

Family

ID=65526036

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200088A CR20200088A (es) 2017-08-29 2018-08-28 Compuestos espirocíclicos y sus métodos de preparación y uso

Country Status (24)

Country Link
US (1) US11161856B2 (es)
EP (1) EP3675848B1 (es)
JP (1) JP7177825B2 (es)
KR (1) KR20200046053A (es)
CN (1) CN111032034B (es)
AU (1) AU2018326497A1 (es)
BR (1) BR112020003946A2 (es)
CA (1) CA3072926A1 (es)
CL (1) CL2020000463A1 (es)
CO (1) CO2020001715A2 (es)
CR (1) CR20200088A (es)
DO (1) DOP2020000040A (es)
EA (1) EA202090296A1 (es)
EC (1) ECSP20013332A (es)
ES (1) ES2914363T3 (es)
IL (1) IL272578A (es)
JO (1) JOP20200022A1 (es)
MA (1) MA50045A (es)
MX (1) MX2020002254A (es)
PE (1) PE20200665A1 (es)
PH (1) PH12020500371A1 (es)
RU (1) RU2020107039A (es)
SG (1) SG11202000984YA (es)
WO (1) WO2019046330A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028085B1 (ru) 2012-01-06 2017-10-31 Эбайд Терапьютикс, Инк. Карбаматные соединения и их применение
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
EP3675848B1 (en) 2017-08-29 2022-03-23 H. Lundbeck A/S Spirocycle compounds and methods of making and using same
KR20200046061A (ko) 2017-08-29 2020-05-06 룬드벡 라 졸라 리서치 센터 인코포레이티드 스피로사이클 화합물 및 이를 제조하고 사용하는 방법
CN112088001A (zh) 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂
CN111505410B (zh) * 2020-04-02 2022-07-29 矽力杰半导体技术(杭州)有限公司 调光模式检测电路、方法和无调光检测电路及照明系统
WO2021214550A1 (en) 2020-04-21 2021-10-28 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
TW202229255A (zh) 2020-11-13 2022-08-01 丹麥商Ｈ 朗德貝克公司 Magl抑制劑
WO2023213854A1 (en) * 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004529113A (ja) 2001-03-07 2004-09-24 ファイザー・プロダクツ・インク ケモカイン受容体活性のモジュレーター
CA2665804A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
WO2009111550A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Nicotinic acetylcholine receptor sub-type selective amides of diazabicycloal kanes
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
ES2735411T3 (es) 2009-10-23 2019-12-18 Janssen Pharmaceutica Nv Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina
JP2013521290A (ja) 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション Ｍｇｌｕｒ２の正のアロステリックモジュレータ
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
EA028085B1 (ru) * 2012-01-06 2017-10-31 Эбайд Терапьютикс, Инк. Карбаматные соединения и их применение
UA116547C2 (uk) 2012-09-25 2018-04-10 Ф. Хоффманн-Ля Рош Аг Біциклічні похідні
EP3016653A4 (en) 2013-07-03 2017-02-22 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US9771341B2 (en) 2015-03-18 2017-09-26 Abide Therapeutics, Inc. Piperazine carbamates and methods of making and using same
AU2016304408B2 (en) 2015-07-31 2019-02-21 Pfizer Inc., 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors
EP3377060B1 (en) 2015-11-20 2020-08-19 Lundbeck La Jolla Research Center, Inc. Pyrazole derivatives, processes for their preparation and uses thereof
WO2017197192A1 (en) 2016-05-12 2017-11-16 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
KR20200046061A (ko) 2017-08-29 2020-05-06 룬드벡 라 졸라 리서치 센터 인코포레이티드 스피로사이클 화합물 및 이를 제조하고 사용하는 방법
EP3675848B1 (en) 2017-08-29 2022-03-23 H. Lundbeck A/S Spirocycle compounds and methods of making and using same

Also Published As

Publication number Publication date
US11161856B2 (en) 2021-11-02
EP3675848B1 (en) 2022-03-23
IL272578A (en) 2020-03-31
ES2914363T3 (es) 2022-06-09
EA202090296A1 (ru) 2020-08-03
PE20200665A1 (es) 2020-06-11
JOP20200022A1 (ar) 2020-02-02
RU2020107039A (ru) 2021-09-30
CO2020001715A2 (es) 2020-02-28
SG11202000984YA (en) 2020-03-30
MX2020002254A (es) 2020-07-20
CL2020000463A1 (es) 2020-07-10
PH12020500371A1 (en) 2020-12-07
CN111032034B (zh) 2023-05-02
US20210214375A1 (en) 2021-07-15
BR112020003946A2 (pt) 2020-09-08
MA50045A (fr) 2020-07-08
DOP2020000040A (es) 2020-08-31
JP2020532547A (ja) 2020-11-12
AU2018326497A1 (en) 2020-02-20
CA3072926A1 (en) 2019-03-07
EP3675848A1 (en) 2020-07-08
EP3675848A4 (en) 2021-03-10
KR20200046053A (ko) 2020-05-06
WO2019046330A1 (en) 2019-03-07
JP7177825B2 (ja) 2022-11-24
ECSP20013332A (es) 2020-04-22
CN111032034A (zh) 2020-04-17

Similar Documents

Publication Publication Date Title
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12019501079A1 (en) Magl inhibitors
PH12019501097A1 (en) Magl inhibitors
PH12019502646A1 (en) Pyrazole magl inhibitors
GB2541571A (en) Pharmaceutical compositions
PH12019501102A1 (en) Magl inhibitors
WO2015179559A3 (en) Pyrazole compounds and methods of making and using same
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
MX2017017119A (es) Formulacion de alta concentracion.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy